Would be nice, but all they volunteer is that the adverse event rate is highest in the 30-50 year olds. Given that, I don’t think it makes a material difference
Also more conspiratorially, because I think they would have provided the age-stratified data if it supported their objectives of improving lagging uptake among younger cohorts.